




 COPD is the fourth leading cause of death in the United States and causes  . 2.5 million deaths 
worldwide each year. 1-3 The most frequent cause of 
death in advanced COPD is respiratory failure, but 
in mild and moderate COPD, lung cancer and cardio-
vascular diseases account for two-thirds of the deaths. 4 
 GOLD (Global Initiative for Chronic Obstructive 
Lung Disease) defi nes COPD as a disease state char-
acterized by the presence of airway obstruction that 
is not fully reversible. 5 In these patients, airfl ow 
obstruction is caused by a mixture of small airways 
disease (obstructive bronchiolitis) and parenchymal 
destruction (emphysema); the relative contributions 
vary from person to person. Airway obstruction, 
readily determined by spirometry, has been shown 
to predict an increased mortality rate in the general 
population. 6 Emphysema has been extensively stud-
ied physiologically, pathologically, and at autopsy, 
but not until recent advances in CT scan technology 
has there been a reliable means for its in vivo diag-
nosis and characterization. However, data regarding 
the signifi cance of CT scan-detected emphysema in 
deter mining outcomes are scarce. Studies have shown 
that the presence of emphysema on low-dose chest 
CT scan in a cohort participating in a lung cancer 
screening study is an independent risk factor for lung 
cancer. 7,8 A study that was limited to patients with 
lung cancer showed that CT scan-detected emphy-
sema, but not airway obstruction, was associated with 
a worse prognosis. 9 
 Recently, the presence of emphysema on a CT scan 
has been associated with an increase in mortality in 
a small cohort of patients with COPD, most of whom 
entered the study in advanced stages of the disease. 10 
To date, no relationship between emphysema as 
identifi ed on chest CT scan and mortality in the gen-
eral population or in asymptomatic smokers has been 
reported. In the present study, we explored whether 
the presence and extent of emphysema detected on 
low-dose CT scans are risk factors for mortality from 
COPD or lung cancer among a large cohort of asymp-
tomatic smokers. 
 Objective:  Our objective was to assess the usefulness of emphysema scores in predicting death 
from COPD and lung cancer. 
 Methods:  Emphysema was assessed with low-dose CT scans performed on 9,047 men and women 
for whom age and smoking history were documented. Each scan was scored according to the 
presence of emphysema as follows: none, mild, moderate, or marked. Follow-up time was calcu-
lated from time of CT scan to time of death or December 31, 2007, whichever came fi rst. Cox 
regression analysis was used to calculate the hazard ratio (HR) of emphysema as a predictor of 
death. 
 Results:  Median age was 65 years, 4,433 (49%) were men, and 4,133 (46%) were currently smoking or 
had quit within 5 years. Emphysema was identifi ed in 2,637 (29%) and was a signifi cant predictor of 
death from COPD (HR, 9.3; 95% CI, 4.3-20.2;  P  , .0001) and from lung cancer (HR, 1.7; 95% CI, 
1.1-2.5;  P  5 .013), even when adjusted for age and smoking history. 
 Conclusions:  Visual assessment of emphysema on CT scan is a signifi cant predictor of death from 
COPD and lung cancer.   CHEST 2012; 141(5):1216–1223 
 Abbreviations:  HR  5 hazard ratio; NDI  5 National Death Index 
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 Extent of Emphysema 
 A participant was classifi ed as having no emphysema or any 
emphysema. If emphysema was present, it was rated as mild if 
no discrete areas of decreased attenuation could be identifi ed 
on the CT scan, but the blood vessels were splayed, suggesting 
parenchymal expansion, or there were occasional discrete areas 
of decreased attenuation. The emphysema was rated moderate 
if discrete areas of decreased attenuation could be identifi ed 
that involved less than one-half of the lung parenchyma, and it 
was rated as marked if discrete areas of decreased attenuation 
could be identifi ed as involving more than one-half of the lung 
parenchyma. A score of 0 to 3 was assigned for none, mild, mod-
erate, or marked emphysema, respectively. The four radiologists 
had been working together on interpreting low-dose CT scans 
for  . 5 years and developed the simple criteria regarding the 
presence or absence and extent of emphysema on low-dose 
CT scans. The radiologists and radiology fellow reviewed prior 
low-dose CT scans jointly and agreed to the criteria for the pres-
ence and extent of emphysema. The assessment was documented 
when the screening CT scan was being read. 
 Pack-Years of Cigarette Smoking 
 Detailed information about smoking history was obtained at 
the time of baseline screening and at each subsequent visit using 
a standardized, interviewer-administered questionnaire. Col-
lected data included the age at which habitual smoking began 
and whether the participant continued to smoke during the past 
month. For current smokers, information was obtained on the 
number of packs of cigarettes per day currently being smoked. 
For former smokers, the typical number of packs of cigarettes 
smoked per day and the number of years they smoked were 
obtained as well as the year when they had quit smoking. These 
data were translated into the lifetime cumulative number of 
pack-years of cigarette smoking. For purposes of this report, the 
number of pack-years of smoking was based on the information 
obtained at the time of the baseline CT scan. 
 Deaths 
 All participants were followed regularly as part of the screen-
ing protocol and beyond completion of the study. The date of the 
last attempted contact and the vital status at that time were 
recorded. In the case of death, the date and cause of death were 
obtained from family members, the participant’s physician, or 
both. For further verifi cation, the National Death Index (NDI) 
was searched using the participant’s last name, middle name, fi rst 
name, sex, social security number, date of birth, race, marital 
status, father’s surname, date of last contact, state of residence, 
state of birth, and age at death, if applicable, as matching criteria. 
The fi nal determination of vital status was obtained by com-
bining information from family members, the participant’s physi-
cian, and the results from the NDI search. For purposes of our 
analysis, only participants confi rmed by family members, the phy-
sician, or a defi nite match from NDI were considered to be 
deceased. All others were assumed to be living as of December 31, 
2007. The cause of death was coded according to the  International 
Classifi cation of Diseases, 10th Revision . If the  International 
Classifi cation of Diseases, 10th Revision code was J43-J44 , the 
death was recorded as being due to COPD (emphysema, chronic 
bronchitis, or COPD), and if it was C34, the death was recorded 
as being due to lung cancer. In three participants, the physician in 
charge of terminal illness disagree about the NDI cause of death, 
and in those three cases, physician-reported cause of death was 
used for purposes of these analyses. The readers were blinded 
to the cause of death determination for the presence of emphysema 
or lung cancer on the CT scan. Follow-up time was calculated 
 Materials and Methods 
 Subjects 
 Data for this study were obtained from prospective exami-
nation of a cohort of 9,047 asymptomatic men and women at risk 
for lung cancer who underwent low-dose CT scan screening for 
lung cancer in New York State in June 2000 to December 2007. 
This cohort included subjects who were aged 40 to 85 years at the 
time of enrollment with no prior lung cancer or other cancer (except 
squamous cell or basal cell skin cancer) who were fi t to undergo 
thoracic surgery. Each participant completed a precoded ques-
tionnaire that asked about symptoms that would lead to exclusion 
from the study: hemoptysis, unexplained weight loss, hoarse-
ness, and worsening cough. In accordance with the protocol for 
CT scan screening for lung cancer, 9 all participants had an ungated, 
low-dose CT scan at one of the 12 participating institutions, and 
all consented according to the approved institutional review board, 
Health Insurance Portability and Accountability Act-compliant 
protocol at each institution. If a participant had more than one 
CT scan during the study period, only the fi rst scan was included 
for purposes of this report. 
 Imaging and Reading of the Images 
 The low-dose CT scan was obtained from the lung apices to 
the bases in a single breath at maximum inspiration. Cardiac 
gating and IV contrast material were not used. All interpreta-
tions of the chest CT scans used in this report were performed 
at the coordinating center using standardized criteria. Interpreta-
tion was done fi rst by a radiology fellow (A. O. F.) and then con-
fi rmed by one of four experienced chest radiologists (D. I. M., 
M. C., D. F. Y., C. I. H.). The reader viewed the images on a high-
resolution monitor at its typical window and level settings with 
maximum magnifi cation while scrolling through the images one by 
one. Interpretations were performed using standard lung settings 
(width, 1,500 Hounsfi eld units; level,  2 650 Hounsfi eld units). 
 Manuscript received February 18, 2011; revision accepted 
October 4, 2011. 
 Affi liations: From the Department of Pulmonary Medicine 
(Dr Zulueta), Clinica Universidad de Navarra, University of Navarra, 
Pamplona, Spain; Divisions of General Internal Medicine and 
Pulmonary, Critical Care and Pulmonary Medicine (Dr Wisnivesky) 
and Department of Radiology (Drs Henschke, Farooqi, and 
Yankelevitz and Ms Yip), Mount Sinai School of Medicine, 
New York, NY; and Department of Radiology (Drs McCauley and 
Chen) and Department of Medicine and Division of Pulmonary 
and Critical Care Medicine (Drs Libby, Smith, and Pasmantier), 
Weill Cornell Medical College, New York, NY. 
 Funding/Support: This report has been funded in part by the 
Flight Attendants Medical Research Institute. The screening 
studies were partly supported by National Institutes of Health 
[R01-CA-63393]; the City of New York, Department of Health and 
Mental Hygiene; New York State Offi ce of Science, Technology 
and Academic Research (NYSTAR); General Electric; Kodak; 
Empire Blue Cross and Blue Shield; The Starr Foundation; 
Ernest E. Stempel Foundation; The New York Community Trust; 
The Rogers Family Fund; and AMDeC Foundation, Inc. No 
tobacco funds were used in the acquisition of the data and images 
or in the analysis . 
 Correspondence to: Claudia I. Henschke, PhD, MD, Depart ment 
of Radiology, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl, 
Box 1234, New York, NY 10029; e-mail: Claudia.Henschke@
mountsinai.org 
 © 2012 American College of Chest Physicians. Reproduction 
of this article is prohibited without written permission from the 
American College of Chest Physicians ( http://www.chestpubs.org/
site/misc/reprints.xhtml ). 
 DOI: 10.1378/chest.11-0101 
1218 Original Research
higher for men than for women (30% vs 28%,  P  5 .04) 
and present more frequently in current smokers than 
in former smokers (38% vs 25%,  P  , .0001). The 
prevalence of emphysema increased with increasing 
age ( P  , .0001) and with increasing smoking history 
( P  , .0001). 
 There were 47 deaths from COPD and 100 from 
lung cancer. Unadjusted univariate Kaplan-Meier 
analyses showed an increased mortality from COPD 
( P  , .0001) ( Fig 1A ) and from lung cancer ( P  , .0001) 
among patients with emphysema ( Fig 2A ). Similarly, 
the mortality from COPD ( P  , .0001) and from lung 
cancer ( P  , .0001) increased with increasing extent 
of CT scan-detected emphysema ( Figs 1B, 2B ). Even 
when adjusted for potential confounders of age and 
smoking history (pack-years of smoking and time 
since quitting for former smokers), the presence of 
emphysema was a signifi cant predictor of death from 
COPD (hazard ratio [HR], 9.3; 95% CI, 4.3-20.2; 
 P  , .0001) ( Table 2 ). When considering the extent of 
emphysema rather than merely its presence, it was 
mild in 1,908 participants (21%), moderate in 512 (6%), 
and marked in 217 (2%), and all three were indepen-
dent risk indicators for death from COPD ( Table 2 ) 
when adjusted for potential confounders of age and 
smoking history. 
 The presence of emphysema was a signifi cant pre-
dictor of death from lung cancer (HR, 1.7; 95% CI, 
1.1-2.5;  P  5 .013) when adjusted for potential con-
founders of age, pack-years of smoking, current or 
had quit smoking within 4 years of enrollment, and 
had quit 5 to 10 years prior to enrollment ( Table 3 ). 
When considering the extent of emphysema, only 
marked emphysema was an independent risk indi-
cator of death from lung cancer ( Table 3 ). 
 Discussion 
 The main fi nding of this study is that the presence 
of emphysema on an ungated, low-dose chest CT scan 
is an independent predictor of death from COPD or 
lung cancer. These data show that in asymptomatic 
individuals, even the presence of mild emphysema is 
an imaging marker for increase risk of death. Future 
studies should evaluate whether early intervention, 
be it smoking cessation or treatment of COPD, could 
reduce the risk for early mortality. 
 Currently, spirometry is the standard method used 
for diagnosing COPD. However, in recent years, 
there has been an increase in the use of CT scan 
for the evaluation of emphysema. Prior studies have 
shown good anatomic correlations between CT scan 
and pathology specimens as well as an association 
between CT scan-detected emphysema with the pres-
ence of airway obstruction on spirometry. 11 Additionally, 
from time of enrollment to time of death or December 31, 2007, 
whichever came fi rst. Median follow-up time was 72.0 months 
(range, 0.0-91.9 months). 
 Statistical Methods 
 The distribution of sex, age, pack-years of smoking for all 
smokers, and years since quitting for former smokers were com-
pared according to the extent of emphysema (none, mild, mod-
erate, or marked) using the  x 2 test. The Kaplan-Meier method 
was used to estimate survival curves for patients with and without 
emphysema and according to the extent of emphysema. Survival 
curves were compared with the log-rank test. Cox regression 
analysis was used to evaluate the association between the extent 
of emphysema and survival after adjusting for potential con-
founders such as age, sex, and smoking history. All statistical 
analyses were performed with SAS version 9.2 (SAS Institute Inc) 
and two-sided  P values. 
 Results 
 The median age of the 9,047 asymptomatic partic-
ipants at the time of screening was 65 years, and 
median pack-years of smoking was 43 ( Table 1 ); 
4,433 subjects (49%) were men, 8,078 (89%) were 
white, and 8,612 (95%) had completed a high school 
education. All 9,047 were smokers, with pack-years of 
smok ing  , 30 for 2,476 (27%), 30 to 59 for 4,188 (46%), 
and  . 60 for 2,383 (26%). The median pack-years of 
smoking was higher in men than in women (45 vs 42, 
 P  , .0001). There were 3,080 participants (34%) who 
were smoking at the time of the CT scan, and the 
remaining 5,967 had quit prior to enrollment. For the 
former smokers, the median years of quitting was 
15 (range, 0.0-56 years); 1,053 had quit within 5 years of 
enrollment, and 1,040 and 3,874 had quit 5 to 10 years 
and   11 years prior to enrollment, respectively. 
Current smokers were slightly younger than former 
smok ers (median age, 64 vs 65 years, respectively). 
 Emphysema was identifi ed in 2,637 participants 
(29%) ( Table 1 ). The prevalence of emphysema was 
 Table 1— Baseline Characteristics of Study Participants 
According to the Presence of Emphysema 
Characteristic Absent Present Total 
No. subjects 6,410 (71) 2,637 (29) 9,047 (100)
Sex
 Male 3,097 (48) 1,336 (51) 4,433 (49)
 Female 3,313 (52) 1,301 (49) 4,614 (51)
Median age (IQR ) 64 (61-69) 66 (62-70) 65 (61-69 )
Median pack-y (IQR) 39 (25-55) 51 (39-73) 43 (28-61)
Smoking status
Current smoker 1,924 (30) 1,156 (44) 3,080 (34)
Former smoker
 Quit   4 y 731 (11) 322 (12) 1,053 (12)
 Quit 5-10 y 713 (11) 327 (12) 1,040 (11)
 Quit   11 y 3,042 (47) 832 (32) 3,874 (43)
Data are presented as No. (%), unless otherwise indicated. IQR  5 inter-
quartile range.
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relevant when considering that in a similar cohort of 
asymptomatic smokers for which lung function is 
available, one-half of the individuals with emphysema 
on CT scan would not be diagnosed as having COPD 
according to current diagnostic criteria. 7 The asso-
ciation between COPD and lung cancer, perhaps 
related to chronic infl ammation or changes in bronchial 
epithelial gene expression, are further strengthened 
studies have demonstrated that CT scan-detected 
emphysema is an independent risk factor for lung 
cancer. 7,8 The current study expands these fi ndings 
by showing that individuals with emphysema have 
an increased risk of death from COPD and lung can-
cer, further supporting that emphysema on CT scan, 
even if mild and when patients are asymptomatic, 
represents genuine lung disease. This is especially 
 Figure 1. Kaplan-Meier curves showing an increase in the COPD-specifi c deaths for participants with 
emphysema on CT scans. A, Compared with those without emphysema B, As the extent of emphysema 
increases. 
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some degree of emphysema on CT scan. Approxi-
mately one-third of the study cohort had CT scan 
fi ndings of emphysema, a proportion similar to that 
found in other lung cancer screening studies from 
Spain 7 and Japan. 12 As mentioned previously, in one 
by the associations between CT scan evidence for 
emphysema, the diagnosis of lung cancer, and death 
from COPD and lung cancer. 
 The current data also show that a considerable pro-
portion of asymptomatic smokers have evidence of 
 Figure 2. Kaplan-Meier curves showing an increase in lung cancer-specifi c mortality for subjects with 
emphysema on CT scans. A, Compared with those without emphysema. B, As the extent of emphysema 
increases. 
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smoking status. 17 However, in all these reports, COPD 
is defi ned exclusively by airfl ow limitation, and no 
consideration is given to the presence or absence of 
emphysema. The current results, in combination with 
fi ndings of prior studies, 18 support the concept that 
the correlation between COPD and lung cancer risk 
is also valid, and may even be stronger, in the pres-
ence of CT scan-detected emphysema. 
 The fi ndings are important in view of the increased 
use of CT scan for clinical purposes and, potentially, 
in the future for more extensive lung cancer screen-
ing. First, the presence of emphysema on the CT scan 
refl ects a greater risk for early death from COPD. 
This information may help in selecting individuals 
who may benefi t the most from smoking cessation and, 
potentially, from early treatment of COPD. Second, 
the presence of emphysema provides important infor-
mation about an individual’s risk for lung cancer 
mortality and their selection as high-risk candidates 
for early lung cancer detection studies. 
 The current study has strengths and limitations. 
Data were obtained from a large sample of asymp-
tomatic volunteers from the general population. The 
cohort was followed prospectively, which allowed us 
to assess the long-term outcomes of patients with and 
without emphysema on CT scan. The study cohort 
consisted primarily of elderly patients whose smok-
ing exposure ranged from low, moderate, and high 
levels of tobacco use. Information on cause of death 
was obtained from death certifi cates, and inaccura-
cies of these have been documented. Studies have 
also shown that COPD frequently is not listed as the 
cause of death in these patients; thus, mortality from 
COPD may be underestimated in our sample. 1 It 
is, therefore, possible that the association between 
emphysema on CT scan and death from COPD is 
even stronger than that observed in our cohort. Another 
limitation may be related to the small number of 
deaths from COPD in our cohort, although this is 
expected in a population mostly comprising asymp-
tomatic individuals. In the current report, neither 
airfl ow measurements nor CT scan assessment of the 
airways were used; thus, the focus was on emphysema 
alone, and comparisons with the predictive potential 
of airway disease could not be made. Finally, we used 
visual scores to assess the presence and extent of 
emphysema, although quantitative standardized assess-
ment with computer algorithms also could be used. 
However, the advantage in our study is that visual 
assessment does not require additional software and 
is simple, and previous studies have shown the valid-
ity of this approach. 19-22 
 In conclusion, emphysema frequently is present 
on chest CT scans of smokers and predicts early 
death from COPD or lung cancer. These data pro-
vide strong evidence regarding the validity and utility 
of these studies, one-half of the participants with 
emphysema (15% of the entire cohort) had normal 
lung function, and the presence of emphysema was 
found to predict a diagnosis of lung cancer even among 
patients with normal spirometry. 7 These results com-
bined highlight the importance of detecting emphy-
sema on CT scan, irrespective of the presence or 
absence of airfl ow limitation. 
 The data also confi rm the aforementioned reports 
linking the presence of CT scan-detected emphy-
sema to an increased risk of lung cancer. Long-term 
follow-up in the Lung Health Study has shown that 
lung cancer is the most common cause of death 
among smokers and former smokers with asymp-
tomatic COPD. 13 Epidemiologic studies have shown 
that lung function measured by spirometry predicts 
mortality not only in patients with COPD, but also in 
the general population. 14-17 Some of these studies 
show this relationship to hold true independent of 
 Table 2— Adjusted Hazard for Deaths From COPD 
and Deaths From COPD According to the Extent 
of Emphysema 
Variables in the Model HR 95% CI
Emphysema alone 12.2 5.7-26.2
 Adjusted for:
  Age 11.1 5.2-23.8
  Age and pack-y 10.4 4.8-22.5
  Age, pack-y, and smoking status 9.3 4.3-20.2
According to extent of emphysema
 Mild 3.2 1.2-8.3
 Moderate 22.3 9.5-52.3
 Marked 34.7 13.9-86.6
 Age 1.1 1.1-1.2
 Pack-y 1.0 1.0-1.0
 Current smoker or quit within 4 y 2.4 1.1-5.0
 Former smokers who quit 5-10 y 
  prior to study
3.3 1.4-8.0
HR  5 hazard ratio.
 Table 3— Adjusted Hazard for Lung Cancer Deaths 
and Lung Cancer Deaths According to the Extent 
of Emphysema 
Variables in the Model HR 95% CI
Emphysema alone 2.3 1.6-3.4
 Adjusted for:
  Age 2.1 1.5-3.2
  Age and pack-y 1.8 1.2-2.7
  Age, pack-y, and smoking status 1.7 1.1-2.5
According to extent of emphysema
 Mild 1.4 0.9-2.3
 Moderate 1.8 0.9-3.4
 Marked 3.2 1.5-6.7
 Age 1.1 1.0-1.1
 Pack-y 1.0 1.0-1.0
 Current smoker or quit within 4 y 2.4 1.5-4.0
 Former smokers who quit 5-10 y prior to study 1.3 0.6-2.7
See Table 2 for expansion of abbreviation.
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these patients. 
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